Kailera Therapeutics is trading at $12.06, up 5.51%, amid a 2.10% biotech-sector gain that may be a tailwind; available evidence does not confirm it caused the move. - No clear company-specific announcement for October 20 surfaced in the search. - The reported Phase 3 enrollment completion dates to September, so it does not establish a new catalyst for this move.